Selected research
Industry Research
Recombinant Plasma Protein Therapeutics Industry Research Report 2026
Market perspective
The global Recombinant Plasma Protein Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Recombinant Plasma Protein Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Recombinant Plasma Protein Therapeutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Recombinant Plasma Protein Therapeutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Recombinant Plasma Protein Therapeutics include Takeda, Novo Nordisk A/S, Pfizer, Pharming Group, Octapharma, CSL Limited, Bioverativ Therapeutics and Aptevo Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Recombinant Plasma Protein Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Plasma Protein Therapeutics Market by Company
Takeda
Novo Nordisk A/S
Pfizer
Pharming Group
Octapharma
CSL Limited
Bioverativ Therapeutics
Aptevo Therapeutics
Recombinant Plasma Protein Therapeutics Segment by Type
Recombinant Coagulation Factors
Human C1 Esterase Inhibitor
Recombinant Plasma Protein Therapeutics Segment by Application
Von Willebrand Disease
Hemophilia A
Hemophilia B
Recombinant Plasma Protein Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Plasma Protein Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Plasma Protein Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Plasma Protein Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Recombinant Plasma Protein Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Recombinant Plasma Protein Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Recombinant Plasma Protein Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Coagulation Factors
- Human C1 Esterase Inhibitor
Applications
- Von Willebrand Disease
- Hemophilia A
- Hemophilia B
Companies covered
- Takeda
- Novo Nordisk A/S
- Pfizer
- Pharming Group
- Octapharma
- CSL Limited
- Bioverativ Therapeutics
- Aptevo Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Recombinant Plasma Protein Therapeutics Market Size (2021-2032)
- 2.2.2 Global Recombinant Plasma Protein Therapeutics Sales (2021-2032)
- 2.2.3 Global Recombinant Plasma Protein Therapeutics Market Average Price (2021-2032)
- 2.3 Recombinant Plasma Protein Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Recombinant Coagulation Factors
- 2.3.3 Human C1 Esterase Inhibitor
- 2.4 Recombinant Plasma Protein Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Von Willebrand Disease
- 2.4.3 Hemophilia A
- 2.4.4 Hemophilia B
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Recombinant Plasma Protein Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Recombinant Plasma Protein Therapeutics Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Recombinant Plasma Protein Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Recombinant Plasma Protein Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Recombinant Plasma Protein Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Recombinant Plasma Protein Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Recombinant Plasma Protein Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of Recombinant Plasma Protein Therapeutics, Established Date
- 3.9 Global Recombinant Plasma Protein Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Recombinant Plasma Protein Therapeutics Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Novo Nordisk A/S
- 4.2.1 Novo Nordisk A/S Company Information
- 4.2.2 Novo Nordisk A/S Business Overview
- 4.2.3 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product Portfolio
- 4.2.5 Novo Nordisk A/S Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Recombinant Plasma Protein Therapeutics Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Pharming Group
- 4.4.1 Pharming Group Company Information
- 4.4.2 Pharming Group Business Overview
- 4.4.3 Pharming Group Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pharming Group Recombinant Plasma Protein Therapeutics Product Portfolio
- 4.4.5 Pharming Group Recent Developments
- 4.5 Octapharma
- 4.5.1 Octapharma Company Information
- 4.5.2 Octapharma Business Overview
- 4.5.3 Octapharma Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Octapharma Recombinant Plasma Protein Therapeutics Product Portfolio
- 4.5.5 Octapharma Recent Developments
- 4.6 CSL Limited
- 4.6.1 CSL Limited Company Information
- 4.6.2 CSL Limited Business Overview
- 4.6.3 CSL Limited Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 CSL Limited Recombinant Plasma Protein Therapeutics Product Portfolio
- 4.6.5 CSL Limited Recent Developments
- 4.7 Bioverativ Therapeutics
- 4.7.1 Bioverativ Therapeutics Company Information
- 4.7.2 Bioverativ Therapeutics Business Overview
- 4.7.3 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio
- 4.7.5 Bioverativ Therapeutics Recent Developments
- 4.8 Aptevo Therapeutics
- 4.8.1 Aptevo Therapeutics Company Information
- 4.8.2 Aptevo Therapeutics Business Overview
- 4.8.3 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio
- 4.8.5 Aptevo Therapeutics Recent Developments
5 Global Recombinant Plasma Protein Therapeutics Market Scenario by Region
- 5.1 Global Recombinant Plasma Protein Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Recombinant Plasma Protein Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global Recombinant Plasma Protein Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global Recombinant Plasma Protein Therapeutics Sales by Region: 2027-2032
- 5.3 Global Recombinant Plasma Protein Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global Recombinant Plasma Protein Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global Recombinant Plasma Protein Therapeutics Revenue by Region: 2027-2032
- 5.4 North America Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
- 5.4.1 North America Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Recombinant Plasma Protein Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America Recombinant Plasma Protein Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Recombinant Plasma Protein Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe Recombinant Plasma Protein Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
- 5.7.1 South America Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Recombinant Plasma Protein Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America Recombinant Plasma Protein Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Recombinant Plasma Protein Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global Recombinant Plasma Protein Therapeutics Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global Recombinant Plasma Protein Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global Recombinant Plasma Protein Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Recombinant Plasma Protein Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Recombinant Plasma Protein Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global Recombinant Plasma Protein Therapeutics Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global Recombinant Plasma Protein Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global Recombinant Plasma Protein Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Recombinant Plasma Protein Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Recombinant Plasma Protein Therapeutics Value Chain Analysis
- 8.1.1 Recombinant Plasma Protein Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Recombinant Plasma Protein Therapeutics Production Mode & Process
- 8.2 Recombinant Plasma Protein Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Recombinant Plasma Protein Therapeutics Distributors
- 8.2.3 Recombinant Plasma Protein Therapeutics Customers
9 Global Recombinant Plasma Protein Therapeutics Analyzing Market Dynamics
- 9.1 Recombinant Plasma Protein Therapeutics Industry Trends
- 9.2 Recombinant Plasma Protein Therapeutics Industry Drivers
- 9.3 Recombinant Plasma Protein Therapeutics Industry Opportunities and Challenges
- 9.4 Recombinant Plasma Protein Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst